×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLLS – cellectis s.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
11:09 pm
clls
Cellectis S.A. (NASDAQ: CLLS) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/19
11:07 pm
clls
Cellectis S.A. (NASDAQ: CLLS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/13
06:07 pm
clls
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Medium
Report
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
3/7
05:35 pm
clls
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 [Yahoo! Finance]
Medium
Report
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 [Yahoo! Finance]
3/7
04:30 pm
clls
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Low
Report
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
2/27
03:02 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Medium
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
2/24
01:30 am
clls
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Medium
Report
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
2/19
02:09 am
clls
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Low
Report
Cellectis S.A. (NASDAQ: CLLS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
3/13/2025
06:07 pm
clls
cellectis s.a. - american depositary shares
MISS
Report
-3.9%
cellectis s.a. - american depositary shares
3/13/2025
06:07 pm
clls
cellectis s.a. - american depositary shares
MISS
Report
-3.9%
cellectis s.a. - american depositary shares
3/13/2025
06:07 pm
clls
cellectis s.a. - american depositary shares
MISS
Report
-3.9%
cellectis s.a. - american depositary shares
3/13/2025
06:07 pm
clls
cellectis s.a. - american depositary shares
MISS
Report
-3.9%
cellectis s.a. - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
05:00 pm
clls
Form 6-K Cellectis S.A. For: Mar 31
Medium
Report
Form 6-K Cellectis S.A. For: Mar 31
3/14
04:57 pm
clls
Form 20-F/A Cellectis S.A. For: Dec 31
Medium
Report
Form 20-F/A Cellectis S.A. For: Dec 31
3/14
06:03 am
clls
Form 20-F Cellectis S.A. For: Dec 31
High
Report
Form 20-F Cellectis S.A. For: Dec 31
3/7
04:39 pm
clls
Form 6-K Cellectis S.A. For: Mar 07
Low
Report
Form 6-K Cellectis S.A. For: Mar 07
2/24
06:00 am
clls
Form 6-K Cellectis S.A. For: Feb 24
Low
Report
Form 6-K Cellectis S.A. For: Feb 24
1/30
09:36 pm
clls
Form SCHEDULE 13D/A Cellectis S.A. Filed by: Bpifrance Participations SA
Low
Report
Form SCHEDULE 13D/A Cellectis S.A. Filed by: Bpifrance Participations SA
1/24
09:52 am
clls
Form SCHEDULE 13D/A Cellectis S.A. Filed by: ASTRAZENECA PLC
Medium
Report
Form SCHEDULE 13D/A Cellectis S.A. Filed by: ASTRAZENECA PLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/17
3 “Strong Buy” Healthcare Stocks That Can Double in 2020 [Yahoo! Finance News]
14.3%
4/13 Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer 13.0%
2/18 Cellectis and Servier Expand Collaboration on UCART19 Products 9.2%
10/29 Form 6-K Cellectis S.A. For: Oct 29 7.5%
8/7 Cellectis: Monthly Information on Share Capital and Company Voting Rights 6.6%
1/9 Cellectis: Monthly Information on Share Capital and Company Voting Rights 5.7%
8/17 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.0%
10/31 Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST 4.0%
11/8 Cellectis: Monthly information on share capital and company voting rights 3.8%
2/12 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.5%
4/13 Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer 13.0%
2/18 Cellectis and Servier Expand Collaboration on UCART19 Products 9.2%
10/29 Form 6-K Cellectis S.A. For: Oct 29 7.5%
8/7 Cellectis: Monthly Information on Share Capital and Company Voting Rights 6.6%
1/9 Cellectis: Monthly Information on Share Capital and Company Voting Rights 5.7%
8/17 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.0%
10/31 Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST 4.0%
11/8 Cellectis: Monthly information on share capital and company voting rights 3.8%
2/12 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.5%
TOP News Decliners
3/6
Cellectis: Monthly Information on Share Capital and Company Voting Rights
-17.3%
2/21 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $22.00 price target on the stock. -9.5%
4/29 Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT -8.3%
4/15 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -8.0%
3/10 Form 6-K Cellectis S.A. For: Mar 10 -8.0%
10/1 Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates -7.9%
3/5 Cellectis SA (CLLS) Q4 2019 Earnings Call Transcript [The Motley Fool] -7.0%
6/5 Cellectis: Monthly Information on Share Capital and Company Voting Rights -5.9%
4/23 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.7%
4/2 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.6%
2/21 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $22.00 price target on the stock. -9.5%
4/29 Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT -8.3%
4/15 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -8.0%
3/10 Form 6-K Cellectis S.A. For: Mar 10 -8.0%
10/1 Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates -7.9%
3/5 Cellectis SA (CLLS) Q4 2019 Earnings Call Transcript [The Motley Fool] -7.0%
6/5 Cellectis: Monthly Information on Share Capital and Company Voting Rights -5.9%
4/23 Cellectis SA (NASDAQ: CLLS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.7%
4/2 Cellectis SA (NASDAQ: CLLS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: